Literature DB >> 20643235

Advances in the biology of bone metastasis: how the skeleton affects tumor behavior.

Julie A Sterling1, James R Edwards, T John Martin, Gregory R Mundy.   

Abstract

It is increasingly evident that the microenvironment of bone can influence the cancer phenotype in many ways that favor growth in bone. The ability of cancer cells to adhere to bone matrix and to promote osteoclast formation are key requirements for the establishment and growth of bone metastases. Several cytokine products of breast cancers (e.g. PTHrP, IL-11, IL-8) have been shown to act upon host cells of the bone microenvironment to promote osteoclast formation, allowing for excessive bone resorption. The increased release of matrix-derived growth factors, especially TGF-β, acts back upon the tumor to facilitate further tumor expansion and enhance cytokine production, and also upon osteoblasts to suppress bone formation. This provides a self-perpetuating cycle of bone loss and tumor growth within the skeleton. Other contributing factors favoring tumor metastasis and colonization in bone include the unique structure and stiffness of skeletal tissue, along with the diverse cellular composition of the marrow environment (e.g. bone cells, stromal fibroblasts, immune cells), any of which can contribute to the phenotypic changes that can take place in metastatic deposits that favor their survival. Additionally, it is also apparent that breast cancer cells begin to express different bone specific proteins as well as proteins important for normal breast development and lactation that allow them to grow in bone and stimulate bone destruction. Taken together, these continually emerging areas of study suggest new potential pathways important in the pathogenesis of bone metastasis and potential areas for targeting therapeutics.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643235     DOI: 10.1016/j.bone.2010.07.015

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  79 in total

1.  Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Authors:  Bhavani Krishnan; Thomas L Smith; Purnima Dubey; Michael E Zapadka; Frank M Torti; Mark C Willingham; E Ann Tallant; Patricia E Gallagher
Journal:  Prostate       Date:  2012-05-29       Impact factor: 4.104

2.  TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.

Authors:  Rachelle W Johnson; Mai P Nguyen; Susan S Padalecki; Barry G Grubbs; Alyssa R Merkel; Babatunde O Oyajobi; Lynn M Matrisian; Gregory R Mundy; Julie A Sterling
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

Review 3.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

4.  Demethoxycucumin protects MDA-MB-231 cells induced bone destruction through JNK and ERK pathways inhibition.

Authors:  Xiaofeng Shen; Xiaochen Sun; Hua Chen; Binjie Lu; Yuanyuan Qin; Chenxi Zhang; Guoqiang Liang; Jiangping Wang; Pengfei Yu; Li Su; Qihan Ma; Yuwei Li
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-05       Impact factor: 3.333

5.  Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis.

Authors:  Qing Chen; Joan Massagué
Journal:  Clin Cancer Res       Date:  2012-08-09       Impact factor: 12.531

6.  Lentivirus transduction of human osteoclast precursor cells and differentiation into functional osteoclasts.

Authors:  Margaret L Ramnaraine; Wendy E Mathews; Denis R Clohisy
Journal:  Bone       Date:  2011-10-01       Impact factor: 4.398

7.  Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner.

Authors:  Denise Buenrostro; Kristin A Kwakwa; Nicole E Putnam; Alyssa R Merkel; Joshua R Johnson; James E Cassat; Julie A Sterling
Journal:  Bone       Date:  2018-05-16       Impact factor: 4.398

8.  Development and characterization of murine models of medulloblastoma extraneural growth in bone.

Authors:  Jessica M Grunda; Dezhi Wang; Gregory A Clines
Journal:  Clin Exp Metastasis       Date:  2013-03-15       Impact factor: 5.150

Review 9.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

10.  Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.

Authors:  Ah Young Jun; Hyun-Jeong Kim; Kwang-Kyun Park; Kun Ho Son; Dong Hwa Lee; Mi-Hee Woo; Won-Yoon Chung
Journal:  Invest New Drugs       Date:  2013-05-15       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.